If the IV drug works, then the following oral drug will work. But Amgen will steal this company long before then.
If IV And oral OM have survival benefits it will change the HF care map, as the two formulations provide a continuity of care in the acute and out patient setting. They can be seen as one.
Big pharma is out of ideas, except acquisitions. There's no reason why they will not throw 5-10 per share on CYTK. GLA.